Patient-specific, high-sensitivity spectral CT for assessment of pancreatic cancer

用于评估胰腺癌的患者特异性高灵敏度能谱 CT

• 批准号: 10296757
• 负责人: Jianan Grace Gang
• 金额: $ 64.3万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-22 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10296757
• 关键词: 3D Print; Achievement; Algorithms; Anatomy; Artificial Intelligence; Automobile Driving; Biological Markers; Biological Products; Calibration; Characteristics; Clinical; Clinical Trials; Complement; Complex; Computed Tomography Scanners; Computer software; Contrast Media; Data; Dependence; Detection; Diagnosis; Diagnostic; Disease; Disease Management; Enhancing Lesion; Evaluation; Functional Imaging; Goals; Hybrids; Image; Imaging Techniques; Iodine; Joints; Lead; Lesion; Magnetic Resonance Imaging; Malignant neoplasm of pancreas; Measurement; Measures; Methods; Modeling; Morphology; Noise; Organ; Outcome; Pancreas; Patients; Pattern; Performance; Perfusion; Physics; Property; Protocols documentation; Radiation Dose Unit; Radiation exposure; Reproducibility; Roentgen Rays; Selection Bias; Shapes; Source; Staging; Structure; System; Technology; Texture; Theoretical model; Tissues; Treatment Efficacy; Tweens; Vendor; Visualization; Work; X-Ray Computed Tomography; attenuation; base; clinical application; clinical decision-making; clinical translation; contrast enhanced; denoising; design; detector; fluorodeoxyglucose positron emission tomography; imaging approach; imaging biomarker; imaging modality; imaging system; improved; intelligent algorithm; next generation; novel; novel therapeutics; perfusion imaging; predictive modeling; public health relevance; quantitative imaging; response; spectrograph; technology development; tumor; tumor microenvironment

Abstract. The proposed project concentrates on technology developments to enable high sensitivity, bias-tolerant spectral CT for accurate quantitation of iodine concentration. Spectral CT has the potential of providing true quantitative information of tissue composition and provides an avenue for combined functional and structural imaging. High- sensitivity spectral CT accommodates anatomical sites that are traditionally hard to image, and reliable meas- urements of iodine perfusion allow additional quantitative measures such as tissue texture to aid diagnosis and clinical decision making. In the case of pancreatic cancer, the complex tumor microenvironment and the conse- quential poor perfusion characteristics lead to difficulty in diagnosis, staging, and treatment assessment. The need for visualizing low-enhancing lesions and the benefit of extracting quantitative information directly from image data strongly motivate a high-sensitivity imaging modality for reproducible iodine measurements. The need for visualizing low-enhancing lesions and the benefit of extracting quantitative information directly from image data strongly motivate a high-sensitivity imaging modality for reproducible iodine measurements. How- ever, state-of-the-art spectral CT presents large quantitation bias, i.e., inaccuracies in measured iodine concen- tration compared to the truth. We identify three major sources that contribute to quantitation bias: imaging system (e.g., spectrum mismatch), post-processing (e.g., biased estimator), and patient (scatter, beam hardening). The bias effect in current spectral CT cannot be fully eliminated by increasing radiation exposure, and has complex dependencies on the imaging system, imaging techniques, patient habitus, and processing algorithms. This in- accuracy is a major impediment to pancreatic cancer management and quantitative applications in general. The overall goal of this proposal is to develop robust, high-sensitivity spectral CT solutions that will enhance sensi- tivity and reduce variability in iodine quantitation, which in turn enables accurate, high-performance spectral biomarkers for disease management. The following specific aims will be pursued: (1) to develop an end-to-end, modular theoretical model for robust spectral CT design and optimization, (2) to develop bias-tolerant processing pipeline, and (3) to implement and evaluate high performance, hybrid spectral CT solutions on an experimental CT bench. Completion of the proposed efforts enables robust, high sensitivity spectral CT for improved tumor detection and characterization through accurate, high performance spectral biomarkers. Vendor- and spectral technology-independent outcomes of the proposal include: optimized, patient-specific protocols; post-processing pipelines that are robust against quantitative bias and variability; and the next generation spectral CT system designs for enhanced iodine quantitation. Achievements from the proposed project will improve sensitivity and quantitation accuracy of iodinated contrast media in spectral CT which enables quantitative diagnostics and treatment assessment using robust iodine biomarkers across a broad range of clinical applications.

抽象的。 拟议的项目集中在技术开发上，以实现高灵敏度、容忍偏差的光谱 用于准确定量碘浓度的CT。频谱CT有可能提供真正的定量 组织成分信息，为结合功能和结构成像提供了一条途径。高- 灵敏光谱CT可以适应传统上难以成像的解剖部位，以及可靠的测量方法- 输尿管碘灌流允许额外的定量测量，如组织质地，以帮助诊断和 临床决策。在胰腺癌的情况下，复杂的肿瘤微环境和预后。 慢性不良的血流灌注特性导致诊断、分期和治疗评估的困难。这个 对低强度病变进行可视化的需求以及直接从 图像数据强烈推动了可重复测量碘的高灵敏度成像方式的出现。这个 对低强度病变进行可视化的需求以及直接从 图像数据强烈推动了可重复测量碘的高灵敏度成像方式的出现。怎么- 以往，最先进的光谱CT存在很大的定量偏差，即测量的碘浓度不准确。 与事实相比较。我们确定了造成定量偏差的三个主要来源：成像系统 (例如，频谱失配)、后处理(例如，有偏估计器)和患者(散射、波束硬化)。这个 目前光谱CT中的偏置效应不能通过增加辐射曝光量来完全消除，而且具有复杂性 对成像系统、成像技术、患者习惯和处理算法的依赖。这是在- 准确性是胰腺癌治疗和量化应用的主要障碍。这个 这项提议的总体目标是开发强大的、高灵敏度的频谱CT解决方案，以增强感官- 碘定量中的活动性和降低变异性，从而实现准确、高性能的光谱 疾病管理的生物标志物。将追求以下具体目标：(1)开发端到端的、 用于稳健频谱CT设计和优化的模块化理论模型，(2)发展容偏处理 流水线，以及(3)在试验性环境中实施和评估高性能混合频谱CT解决方案 CT长凳。拟议工作的完成使强大的、高灵敏度的光谱CT能够改善肿瘤 通过准确、高性能的光谱生物标记物进行检测和表征。供应商和光谱 该提案的独立于技术的成果包括：优化的、针对患者的方案；后处理 对定量偏差和变异性具有较强抵抗力的管道；以及下一代光谱CT系统 增强碘定量的设计。拟议项目的成果将提高敏感度和 光谱CT中碘化造影剂的定量准确性，使定量诊断和 在广泛的临床应用中使用强健的碘生物标志物进行治疗评估。